Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion;Zytoreduktive Chirurgie und hypertherme intrathorakale Chemotherapieperfusion

Chirurg

Volumn 81, Issue 6, 2010, Pages 557-562

  Hofmann, H S ^a,b   Wiebe, K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Klinik für Thoraxchirurgie des Krankenhauses Barmherzige Brüder Regensburg   (Germany)

Author keywords

Cytoreductive surgery; Hyperthermic intrathoracic chemotherapy perfusion; Multimodal treatment; Pleural tumors; Thoracic surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; HUMAN; HYPERTHERMIC THERAPY; INSTRUMENTATION; MESOTHELIOMA; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURA; PLEURA TUMOR; REGIONAL PERFUSION; THYMOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; MESOTHELIOMA; NEOPLASM STAGING; PLEURA; PLEURAL NEOPLASMS; THYMOMA; THYMUS NEOPLASMS;

EID: 77954083331     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-010-1926-2     Document Type: Article

References (30)

1. Allen KB, Faber LP, Warren WH (1994) Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am 4: 113-126.
2. Ardizzoni A, Pennucci MC, Castagneto B et al (1994) Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 17: 80-82.
3. Baldini EH, Recht A, Strauss GM et al (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63: 334-338.
4. Bogliolo GV, Lerza R, Bottino GB et al (1991) Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 27: 839-842.
5. Brancatisano RP, Joseph MG, McCaughan BC (1991) Pleurectomy for mesothelioma. Med J Aust 154: 455-457, 460.
6. Castagneto B, Zai S, Mutti L et al (2001) Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 31: 303-310.
7. Bree E de, Ruth S van, Baas P et al (2002) Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 121: 480-487.
8. Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7: 5.
9. Goey SH, Eggermont AM, Punt CJ et al (1995) Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 72: 1283-1288.
10. Knappmann J (1972) Observations made at post mortem examination in 251 cases of mesothelioma in Hamburg (1958-1968). Pneumologie 148: 60-65.
11. Lerner HJ, Schoenfeld DA, Martin A et al (1983) Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52: 1981-1985.
12. Merritt N, Blewett CJ, Miller JD et al (2001) Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78: 171-174.
13. Mustafa KY, Selig WM, Burhop KE et al (1986) Hyperthermia-induced pulmonary edema. J Appl Physiol 60: 1980-1985.
14. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA (2008) Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 34: 886-891.
15. Pistolesi M, Rusthoven J (2004) Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 126: 1318-1329.
16. Ratto GB, Civalleri D, Esposito M et al (1999) Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 117: 759-765.
17. Refaely Y, Simansky DA, Paley M et al (2001) Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 72: 366-370.
18. Richards WG, Zellos L, Bueno R et al (2006) Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24: 1561-1567.
19. Ruffini E, Mancuso M, Oliaro A et al (1997) Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc Surg 113: 55-63.
20. Rusch VW, Niedzwiecki D, Tao Y et al (1992) Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10: 1001-1006.
21. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117: 54-63; discussion 63-55.
22. Thomas CR, Wright CD, Loehrer PJ (1999) Thymoma: state of the art. J Clin Oncol 17: 2280-2289.
23. Tilleman TR, Richards WG, Zellos L et al (2009) Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138: 405-411.
24. Meerbeeck JP van, Gaafar R, Manegold C et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889.
25. Ruth S van, Baas P, Haas R et al (2003) Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10: 176-182.
26. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
27. Wilkins KB, Sheikh E, Green R et al (1999) Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 230: 562-572; discussion 572-564.
28. Yap BS, Benjamin RS, Burgess MA, Bodey GP (1978) The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma. Cancer 42: 1692-1696.
29. Yellin A, Simansky DA, Paley M, Refaely Y (2001) Hyperthermic pleural perfusion with cisplatin: early clinical experience. Cancer 92: 2197-2203.
30. Zellos L, Richards WG, Capalbo L et al (2009) A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 137: 453-458.